- Home
- FAAS vs CUE Comparison
FAAS vs CUE Comparison
Compare FAAS & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAAS
- CUE
- Stock Information
- Founded
- FAAS 2021
- CUE 2014
- Country
- FAAS Indonesia
- CUE United States
- Employees
- FAAS N/A
- CUE N/A
- Industry
- FAAS
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- FAAS
- CUE Health Care
- Exchange
- FAAS NYSE
- CUE Nasdaq
- Market Cap
- FAAS 48.2M
- CUE 48.0M
- IPO Year
- FAAS N/A
- CUE 2018
- Fundamental
- Price
- FAAS $0.56
- CUE $0.68
- Analyst Decision
- FAAS
- CUE Strong Buy
- Analyst Count
- FAAS 0
- CUE 3
- Target Price
- FAAS N/A
- CUE $3.00
- AVG Volume (30 Days)
- FAAS 4.8M
- CUE 311.2K
- Earning Date
- FAAS 01-01-0001
- CUE 08-13-2025
- Dividend Yield
- FAAS N/A
- CUE N/A
- EPS Growth
- FAAS N/A
- CUE N/A
- EPS
- FAAS N/A
- CUE N/A
- Revenue
- FAAS $57,730,593.00
- CUE $7,991,000.00
- Revenue This Year
- FAAS N/A
- CUE N/A
- Revenue Next Year
- FAAS N/A
- CUE $23.84
- P/E Ratio
- FAAS N/A
- CUE N/A
- Revenue Growth
- FAAS 38.16
- CUE 13.83
- 52 Week Low
- FAAS $0.16
- CUE $0.45
- 52 Week High
- FAAS $5.95
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- FAAS 47.96
- CUE 47.91
- Support Level
- FAAS $0.55
- CUE $0.65
- Resistance Level
- FAAS $0.65
- CUE $0.71
- Average True Range (ATR)
- FAAS 0.07
- CUE 0.08
- MACD
- FAAS -0.02
- CUE 0.00
- Stochastic Oscillator
- FAAS 31.64
- CUE 38.62
About FAAS DIGIASIA CORP
DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.